- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04962984
Thrombin Generation in Beta-thalassemia Major (TG-THAL)
July 5, 2021 updated by: Central Hospital, Nancy, France
Evaluation of Hypercoagulability by Thrombin Generation Test in Beta-thalassemia Major
This study aims to evaluate the persistence of a hypercoagulable state in chronically-transfused patients with beta thalassemia major, by using the thrombin generation test (performed in whole blood and plasma).
Patients will be compared with 2 control groups: 1/ healthy volunteers and 2/ carriers of beta-thalassemia trait
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 70 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient with de Beta-thalassemia major
- Patient with regular blood transfusion regimen (every 4 - 6 weeks)
- informed and signed consent
- weight > 30kg
- Hemoglobin > 7g/dL
Exclusion Criteria:
- Emergency situation
- Patients receiving antithrombotic drugs (anticoagulants such as Vitamin K antagonism, heparin or direct oral anticoagulant) or antiplatelet drugs;
- women of childbearing age without contraception
- pregnancy
- deprivation of liberty
- no consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: THAL +
patients with beta thalassemia major, requiring blood transfusion regimen.
Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).
|
additional blood sampling for coagulation tests
|
Sham Comparator: THAL -
Patients with beta thalassemia trait, matched with THAL + for age and gender.
An unique blood sampling of 24 millilters will be performed.
|
additional blood sampling for coagulation tests
|
Sham Comparator: Healthy volunteers
healthy subjects, matched with THAL + for age and gender.
An unique blood sampling of 24 millilters will be performed.
|
additional blood sampling for coagulation tests
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of hypercoagulability using endogenous thrombin potential (ETP) between patients and controls
Time Frame: 6 months
|
Measurement of the area under the thrombin generation curve (ie ETP) in THAL+ patients, before and after transfusion, as compared with ETP measured in controls groups (THAL- and healthy volunteers)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of endogenous thrombin potential's variations before and after transfusion in THAL+ patients over 3 transfusion episodes
Time Frame: 6 months
|
Measurement of the area under the thrombin generation curve before and after transfusion in THAL+ patients over 3 transfusion episodes
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2021
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
September 24, 2018
First Submitted That Met QC Criteria
July 5, 2021
First Posted (Actual)
July 15, 2021
Study Record Updates
Last Update Posted (Actual)
July 15, 2021
Last Update Submitted That Met QC Criteria
July 5, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPRC 2017/TG THAL-MARTIN/MS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Beta Thalassemia Major Anemia
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
CorrectSequence Therapeutics Co., LtdNot yet recruitingBeta-Thalassemia MajorChina
-
First Affiliated Hospital of Guangxi Medical UniversityUnknown
-
Pharmacosmos A/SICON plcRecruitingBeta Thalassemia Major AnemiaDenmark
-
Aga Khan UniversityCompletedBeta Thalassemia Major
-
China Medical University HospitalCompleted
-
bluebird bioCompletedSickle Cell Disease | Beta-Thalassemia MajorFrance
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
EmeraMedCompletedBeta Thalassemia MajorAlbania
Clinical Trials on blood sampling
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance